title: Preoperative concurrent chemotherapy with S-1 and radiotherapy for locally advanced squamous cell carcinoma of the oral cavity: phase I trial.
abstract: BACKGROUND
  This study was conducted to identify a recommended dose for S-1, used in combination with 40-Gy radiation.
  
  
  METHODS
  Thirty patients, 15 each with stage III and IVA oral carcinoma, were enrolled. All patients received a total dose of 40-Gy. For the S-1 treatment, patients were given either the standard Japanese dose, calculated according to body surface area, or a reduced dose. Groups consisting of at least three patients were given S-1 according to one of 8 regimens.
  
  
  RESULTS
  Hematologic toxicity was mild and reversible. The most common nonhematologic toxicity was mucositis. At level 8 that was the standard S-1 dose for 5 days per week for 4 weeks, dose-limiting toxicity was observed when 2 patients had grade 4 mucositis. This level was thus deemed the maximum tolerated dose for the regimen.
  
  
  CONCLUSIONS
  The recommended dose of S-1 with concurrent radiotherapy was the reduced dose of S-1 given for 5 days per week, for 4 consecutive weeks. Preoperative S-1 and concurrent radiotherapy was well tolerate and feasible and warrants a phase II study.
authors.affiliation: Department of Oral Surgery, Oral Restitution, Division of Oral Health Sciences, Graduate School, Tokyo Medical and Dental University, Japan. hiro-harada.osur@tmd.ac.jp
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Harada
authors.forename: Ken
authors.initials: K
authors.lastname: Omura
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy*; D004307:Dose-Response Relationship, Radiation; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D009362:Neoplasm Metastasis; D010094:Oxonic Acid / Q000008:administration & dosage*; D057234:Preoperative Period; D005641:Tegafur / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid
references.citation: Br J Cancer. 2005 Oct 17;93(8):884-9
references.pmid: 16189518
references.citation: Acta Otolaryngol Suppl. 2004 Oct;(554):55-61
references.pmid: 15513513
references.citation: J Clin Oncol. 2006 Sep 1;24(25):4163-9
references.pmid: 16943532
references.citation: Cancer. 2000 Sep 1;89(5):939-45
references.pmid: 10964322
references.citation: Anticancer Drugs. 1996 Jul;7(5):548-57
references.pmid: 8862723
references.citation: Oral Oncol. 2004 Aug;40(7):713-9
references.pmid: 15172641
references.citation: Radiother Oncol. 1995 Aug;36(2):94-100
references.pmid: 7501817
references.citation: Oral Oncol. 1999 Nov;35(6):597-606
references.pmid: 10705096
references.citation: Gan To Kagaku Ryoho. 2001 Oct;28(10):1381-90
references.pmid: 11681245
references.citation: J Craniomaxillofac Surg. 2008 Mar;36(2):75-88
references.pmid: 18222699
references.citation: Cancer Chemother Pharmacol. 2009 Oct;64(5):945-52
references.pmid: 19219603
references.citation: J Clin Oncol. 2006 Mar 1;24(7):1064-71
references.pmid: 16505425
references.citation: J Clin Oncol. 2004 Dec 15;22(24):4867-8
references.pmid: 15520050